← Back to Clinical Trials
Recruiting NCT07792603

NCT07792603 Daily Upgrade Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07792603
Status Recruiting
Phase
Sponsor University of North Carolina, Chapel Hill
Condition Healthy Women
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2026-08-31
Primary Completion 2027-04

Eligibility & Interventions

Sex Female only
Min Age 25 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Essential Amino Acid+Non-Calorie PlaceboHigh intensity Interval Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2026-08-31 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the acute and chronic effects of an essential amino acid supplement (Daily Upgrade EAA+) on metabolomics, amino acid kinetics, metabolic rate, body composition in active adult women. The study consists of an acute randomized double-blind crossover phase comparing EAA+, whey protein isolate, and placebo before high-intensity interval training (HIIT), and a chronic randomized double-blind parallel-arm phase evaluating 3 weeks of EAA+ or placebo supplementation combined with twice-weekly HIIT.

Eligibility Criteria

Inclusion Criteria: * Participant is an adult between the ages of 25-45 years * Participant has a recorded BMI between 18.5-30 kg/m\^2 * Participant is apparently healthy and free from disease, as determined by a health history questionnaire * Participant is a biological female * Participant is naturally menstruating or uses a form of hormonal contraceptive * Participant is recreationally active, based on the International Physical Activity Questionnaire- Short Form * Participant agrees to abstain from caffeine (12 hours), tobacco, alcohol, and exercise for 24 hours prior to testing days * Participant is willing and able to comply with the protocol Exclusion Criteria: * Participant has been diagnosed with chronic heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire. * Participant has a musculoskeletal disorder or injury that would prohibit them from being able to safely complete the study protocol. * Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement * Participant is using, or has consistently used one of the following dietary supplements within 1 month prior to enrollment: whey protein, creatine, essential amino acids * Participant has a known allergy or sensitivity to the placebo or active ingredients * Participant is pregnant or planning to become pregnant * Participant does not speak English or is hearing impaired

Contact & Investigator

Central Contact

Abbie Smith-Ryan, PhD

✉ abbiesmith@unc.edu

📞 919-962-2574

Principal Investigator

Abbie Smith-Ryan, PhD

PRINCIPAL INVESTIGATOR

University of North Carolina, Chapel Hill

Frequently Asked Questions

Who can join the NCT07792603 clinical trial?

This trial is open to female participants only, aged 25 Years or older, up to 45 Years, studying Healthy Women. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07792603 currently recruiting?

Yes, NCT07792603 is actively recruiting participants. Contact the research team at abbiesmith@unc.edu for enrollment information.

Where is the NCT07792603 trial being conducted?

This trial is being conducted at Chapel Hill, United States.

Who is sponsoring the NCT07792603 clinical trial?

NCT07792603 is sponsored by University of North Carolina, Chapel Hill. The principal investigator is Abbie Smith-Ryan, PhD at University of North Carolina, Chapel Hill. The trial plans to enroll 44 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology